EUVIMEDEUVIMED entdecken
Crossref

Identification and assessment of new PIM2 inhibitors for treating hematologic cancers: A combined approach of energy‐based virtual screening and machine learning evaluation

Xi Chen, Jingyi Zhao, Roufen Chen, Liteng Shen, Jialiang Lu, Yu Guo, Xinglong Chi, Shuangshuang Geng, Qingnan Zhang, Zhichao Pan, Xinjun He, Lei Xu und 3 weitere

Archiv der Pharmazie · 2024

DOI: 10.1002/ardp.202300516 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Xi Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou, China. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Program of Traditional Chinese Medicine, Zhejiang, Qiantang Interdisciplinary Foundation of Institute of Basic Medicine and Cancer, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PIM2, part of the PIM kinase family along with PIM1 and PIM3, is often overexpressed in hematologic cancers, fueling tumor growth. Despite its significance, there are no approved drugs targeting it. In response to this challenge, we devised a thorough virtual screening workflow for discovering novel PIM2 inhibitors. Our process includes molecular docking and diverse scoring methods like molecular mechanics generalized born surface area, XGBOOST, and DeepDock to rank potential inhibitors by binding affinities and interaction potential. Ten compounds were selected and subjected to an adequate evaluation of their biological activity. Compound 2 emerged as the most potent inhibitor with an IC 50 of approximately 135.7 nM. It also displayed significant activity against various hematological cancers, including acute myeloid leukemia, mantle cell lymphoma, and anaplastic large cell lymphoma (ALCL). Molecular dynamics simulations elucidated the binding mode of compound 2 with PIM2, offering insights for drug development. These results highlight the reliability and efficacy of our virtual screening workflow, promising new drugs for hematologic cancers, notably ALCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsLeukemia, Myeloid, AcuteHumansAdultMolecular Docking SimulationReproducibility of ResultsStructure-Activity RelationshipEarly Detection of CancerProto-Oncogene ProteinsProtein Serine-Threonine Kinases

Stichwörter der Autor:innen

DeepDockPIM2XGBOOSThematologic cancersvirtual screening

Substanzen

PIM2 protein, humanProto-Oncogene ProteinsProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou, China.
  • Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China.
  • Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of Pharmacy, Hangzhou Medical College, Hangzhou, China.
  • School of Electrical and Information Engineering, Institute of Bioinformatics and Medical Engineering, Jiangsu University of Technology, Changzhou, China.

Förderung

  • Program of Traditional Chinese Medicine, Zhejiang
  • Qiantang Interdisciplinary Foundation of Institute of Basic Medicine and Cancer, Chinese Academy of Sciences

Zitieren

APA

Chen, X., Zhao, J., Chen, R., Shen, L., Lu, J., Guo, Y., Chi, X., Geng, S., Zhang, Q., Pan, Z., He, X., Xu, L., Shen, Z., Yang, H., & Lei, T. (2024). Identification and assessment of new PIM2 inhibitors for treating hematologic cancers: A combined approach of energy‐based virtual screening and machine learning evaluation. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300516

Vancouver

Chen X, Zhao J, Chen R, Shen L, Lu J, Guo Y, et al. Identification and assessment of new PIM2 inhibitors for treating hematologic cancers: A combined approach of energy‐based virtual screening and machine learning evaluation. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202300516

BibTeX
@article{Chen2024,
  author = {Chen, Xi and Zhao, Jingyi and Chen, Roufen and Shen, Liteng and Lu, Jialiang and Guo, Yu and Chi, Xinglong and Geng, Shuangshuang and Zhang, Qingnan and Pan, Zhichao and He, Xinjun and Xu, Lei and Shen, Zheyuan and Yang, Haiyan and Lei, Tao},
  title = {Identification and assessment of new PIM2 inhibitors for treating hematologic cancers: A combined approach of energy‐based virtual screening and machine learning evaluation},
  journal = {Archiv der Pharmazie},
  year = {2024},
  doi = {10.1002/ardp.202300516}
}
Kostenlos starten →